Post-Market Obligations for Food Supplement Importers Under Thai FDA

Brands that treat Thai FDA supplement approval as a finish line tend to run into trouble a year or two later, not at launch. The formula, label, and manufacturing evidence that earned a product its food serial number have to stay current and accurate for the entire time that product remains on the Thai market, and Thai FDA's enforcement authority extends well past the approval decision itself.

What Thai FDA expects once a product is approved

Product approval under MOPH No. 293 is granted on the basis of what was submitted at the time of application: the formula, the label, and the manufacturing evidence. None of that is a snapshot the brand can quietly drift away from. A change to any of these elements implemented without Thai FDA's approval is a compliance violation, regardless of how minor the change feels from the manufacturer's side.

The Food Act B.E. 2522 (1979) gives Thai FDA enforcement authority over food products after they reach the market, including the power to inspect, sample, test, and order withdrawal of non-compliant products. The Orr.7 license holder, the licensed importer, is the party that carries this exposure directly.

Supplement post-market obligations are less formalized than the pharmaceutical world's periodic reporting cycles; there is no PSUR equivalent for supplements in Thailand. That does not mean the obligation is light. Thai FDA's market surveillance program actively samples retail products, and a product found on the shelf that no longer matches its approved label or formula is a straightforward compliance failure, not a paperwork gap that can be resolved with an explanation.

The absence of a formal periodic reporting requirement is, if anything, a reason for more internal discipline, not less. Where a pharmaceutical file forces a manufacturer to revisit its dossier on a fixed schedule, a supplement registration has no equivalent built-in checkpoint. The registration simply sits there, assumed current, until something (a market surveillance sample, a distributor question, a formula change made at the manufacturing level without anyone flagging the Thai implications) surfaces a gap between what is on file with Thai FDA and what is actually being sold. Brands that build their own internal review checkpoint, even an informal annual one, tend to catch these gaps long before Thai FDA does.

Label and formula changes require pre-approval, not notification

Any change to an approved product needs Thai FDA sign-off before it reaches the Thai market. There is no minor variation track that lets a brand implement first and notify later.

A change to the ingredient list, to any ingredient's quantity, or to the sourcing of any ingredient requires a brand-new product approval application; Thai FDA reviews the revised formula as though it were an entirely new product. A change to any required label element, including the importer's name or address if that entity changes, health claims, storage conditions, or any mandatory text, requires re-submission and re-approval, since the food serial number is tied specifically to the approved label and cannot travel with an unapproved one.

If a manufacturer moves production to a new site, or shifts to a different contract manufacturer, fresh GMP evidence for the new site has to be submitted and approved before product from that site can be imported. A packaging format change that affects declared net quantity or storage conditions also needs approval; a purely cosmetic packaging change touching no required label element may be handled differently, but that determination should be confirmed with Thai FDA directly before it is implemented, not assumed.

Global brands run into this most often when a change is decided at headquarters level for reasons that have nothing to do with Thailand specifically: a global reformulation for cost or supply reasons, a manufacturing site consolidation, a packaging redesign rolled out across every market at once. None of those decisions carry an automatic Thailand exemption. Whoever manages the Thai registration needs visibility into global product decisions early enough to file the Thai approval before the new formula, label, or manufacturing site actually reaches the Thai market, not after distribution has already begun on the assumption that the change was minor enough to skip.

Market surveillance and what triggers it

Thai FDA district offices run market surveillance by purchasing products from retail and testing them directly. The tests typically check label compliance (required elements present, food serial number valid), nutrient content against the declared values, the absence of prohibited ingredients or substances, and microbiological safety where relevant to the product type.

A product that fails this testing can trigger a recall notice, an order removing the product from sale, and proceedings against the importer under the Food Act. Penalties for selling food that does not meet standards include imprisonment of up to 2 years, a fine of up to 20,000 THB, or both, and for the Orr.7 license holder a compliance failure can also mean suspension of the license itself, which puts every other product under that license at risk alongside the one that failed.

The license-level consequence is the detail that changes how a compliance failure should be weighed internally. A brand with a single supplement product might treat a labeling discrepancy as a narrow, product-specific problem. An importer holding several product registrations under one Orr.7 license does not have that luxury: a surveillance failure on one product can put the license underpinning every other product at risk, which means the cost of a compliance gap is rarely contained to the product where it was found.

Building post-approval compliance into the plan

The brands that avoid post-market surprises are the ones tracking GMP renewals, import license renewals, and any pending formula or label change against their actual Thai FDA deadlines, rather than discovering a gap when Thai FDA asks a question. A change a manufacturer makes globally without submitting it for Thai approval is a Thailand-specific compliance gap the whole time it goes unreported, whether or not anyone notices immediately.

When a market surveillance inquiry or a consumer complaint does escalate to Thai FDA, speed and precision in the response matter more than most brands expect: an imprecise or delayed answer reads to Thai FDA as evasion, not as normal processing time, and that perception affects how the case is handled from that point forward. The brands that come through an inquiry cleanly are almost always the ones that can produce the requested documentation, the current approved label, the current GMP certificate, the batch records for the product in question, within hours rather than days, because the underlying compliance file was already organized and current before the question was ever asked. DeeMED Consulting maintains post-approval compliance tracking for clients holding active Thai supplement registrations and manages the Thai FDA response when a market surveillance inquiry arises, working from the same Orr.7 import license framework that carries the underlying legal responsibility.